ATF2, activating transcription factor 2, 1386

N. diseases: 122; N. variants: 17
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.370 GeneticVariation disease UNIPROT
CUI: C0025048
Disease: Meconium Aspiration Syndrome
Meconium Aspiration Syndrome 		0.210 Biomarker phenotype MGD
CUI: C0008449
Disease: Congenital anomaly of cartilage
Congenital anomaly of cartilage 		0.200 Biomarker group MGD
CUI: C0029422
Disease: Osteochondrodysplasias
Osteochondrodysplasias 		0.200 Biomarker group MGD
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 AlteredExpression group BEFREE Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues. 1829805 1991
CUI: C0023493
Disease: Adult T-Cell Lymphoma/Leukemia
Adult T-Cell Lymphoma/Leukemia 		0.010 Biomarker disease BEFREE Sequence requirements of ATF2 and CREB binding to the human T-cell leukemia virus type 1 LTR R region. 8610463 1996
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 Biomarker group BEFREE Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type. 9484842 1998
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.200 Biomarker disease RGD Rapid and long-lasting suppression of the ATF-2 transcription factor is a common response to neuronal injury. 9813301 1998
CUI: C0025202
Disease: melanoma
melanoma 		0.100 Biomarker disease BEFREE Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type. 9484842 1998
CUI: C0025048
Disease: Meconium Aspiration Syndrome
Meconium Aspiration Syndrome 		0.210 GeneticVariation phenotype BEFREE Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome. 10364225 1999
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.200 Biomarker disease RGD Persistent phosphorylation of cyclic AMP responsive element-binding protein and activating transcription factor-2 transcription factors following transient cerebral ischemia in rat brain. 10077326 1999
CUI: C0025202
Disease: melanoma
melanoma 		0.100 AlteredExpression disease BEFREE Taken together, our findings suggest that ATF2 contributes to UVC-induced apoptosis through transcriptional silencing of TNFalpha, which balances Fas-mediated cell death in melanoma. 10318823 1999
CUI: C0035220
Disease: Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Newborn 		0.010 GeneticVariation disease BEFREE The ATF-2 null mutants should enhance our understanding of the mechanism of severe neonatal respiratory distress. 10364225 1999
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.370 Biomarker group BEFREE These results indicate a novel role for ATF-2 in cancer cell proliferation and suggest a potential feedback mechanism that regulates MAPK signaling. 11062705 2000
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.070 Biomarker group BEFREE These results indicate a novel role for ATF-2 in cancer cell proliferation and suggest a potential feedback mechanism that regulates MAPK signaling. 11062705 2000
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.200 Biomarker group RGD Activation of cardiac c-Jun NH(2)-terminal kinases and p38-mitogen-activated protein kinases with abrupt changes in hemodynamic load. 11358932 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.400 Biomarker group BEFREE To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines. 11836564 2002
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.370 GeneticVariation disease BEFREE Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers. 11836564 2002
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.080 GeneticVariation disease BEFREE To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines. 11836564 2002
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.070 GeneticVariation phenotype BEFREE To assess the role of the ATF-2 gene as a tumor suppressor in human carcinogenesis, we examined genetic alterations of the ATF-2 gene in 9 breast cancer cell lines, 10 neuroblastoma cell lines and 46 lung cancer cell lines. 11836564 2002
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 GeneticVariation disease BEFREE Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers. 11836564 2002
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.050 GeneticVariation disease BEFREE Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. 11836564 2002
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.050 GeneticVariation disease BEFREE Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. 11836564 2002
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 GeneticVariation disease LHGDN Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers. 11836564 2002
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 GeneticVariation disease BEFREE Genetic variants of the ATF-2 gene were detected in 5 of the 46 (10.6%) lung cancers, but not in neuroblastomas and breast cancers. 11836564 2002